EAM Investors’s Actinium Pharmaceuticals ATNM Stock Holding History

EAM Investors’s Portfolio ATNM Stock Details ATNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-197,021	Closed	-$2.1M	–	259
2022 Q4	$2.1M	Buy	+197,021	New	+$2M	0.43%	84

Other funds holding ATNM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Sentinus LLC Oak Brook, Illinois $1.11B AUM 17.13% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

EAM Investors's ATNM Position: Q1 2023 in Review

EAM Investors sold out of Actinium Pharmaceuticals (ATNM) in Q1 2023, closing a stake of 197,021 shares — an estimated $2.1M sold.

EAM Investors first reported a position in ATNM in Q4 2022 and held it in 1 quarter. The position peaked at $2.1M in Q4 2022. 64 funds tracked by Wall St. Rank hold ATNM as of Q1 2023.

EAM Investors reported no remaining Actinium Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
EAM Investors sold 197,021 Actinium Pharmaceuticals shares in Q1 2023, an estimated $2.1M.
EAM Investors first reported a position in Actinium Pharmaceuticals in Q4 2022 and held it in 1 quarter.
EAM Investors's Actinium Pharmaceuticals position peaked at $2.1M in Q4 2022.
64 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q1 2023.

Based on EAM Investors's 13F filing for Q1 2023, filed 15 May 2023.